XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Feb. 20, 2020
Mar. 31, 2023
Dec. 31, 2022
Fair Value, Option, Quantitative Disclosures [Line Items]      
Contingent consideration liabilities   $ 110,200 $ 111,600
Change in fair value of the contingent financial asset and contingent financial liabilities   1,400  
Progenics      
Fair Value, Option, Quantitative Disclosures [Line Items]      
Aggregate cash payments percentage 40.00%    
Potential payments, high   85,000  
Progenics | Current Liabilities      
Fair Value, Option, Quantitative Disclosures [Line Items]      
Contingent consideration liabilities   99,700  
Progenics | Cash Payments 2022      
Fair Value, Option, Quantitative Disclosures [Line Items]      
Contingent consideration liabilities $ 100,000    
Progenics | Cash Payments 2023      
Fair Value, Option, Quantitative Disclosures [Line Items]      
Contingent consideration liabilities $ 150,000    
Progenics | Net Sales Targets For Azedra      
Fair Value, Option, Quantitative Disclosures [Line Items]      
Potential payments, high   70,000  
Progenics | 1095 commercialization milestone      
Fair Value, Option, Quantitative Disclosures [Line Items]      
Potential payments, high   5,000  
Progenics | 1404 Commercialization Milestone      
Fair Value, Option, Quantitative Disclosures [Line Items]      
Potential payments, high   $ 10,000